Industry
Biotechnology
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.
Loading...
Open
12.41
Mkt cap
790M
Volume
691K
High
12.50
P/E Ratio
-6.51
52-wk high
30.99
Low
11.35
Div yield
N/A
52-wk low
5.86
Portfolio Pulse from Benzinga Newsdesk
October 30, 2024 | 6:54 am
Portfolio Pulse from Benzinga Newsdesk
October 29, 2024 | 10:59 am
Portfolio Pulse from Benzinga Newsdesk
October 28, 2024 | 9:15 pm
Portfolio Pulse from Benzinga Insights
October 28, 2024 | 4:30 pm
Portfolio Pulse from Vandana Singh
October 28, 2024 | 4:16 pm
Portfolio Pulse from Avi Kapoor
October 28, 2024 | 2:15 pm
Portfolio Pulse from Benzinga Newsdesk
October 28, 2024 | 12:32 pm
Portfolio Pulse from Benzinga Newsdesk
October 28, 2024 | 11:04 am
Portfolio Pulse from Benzinga Insights
October 25, 2024 | 2:01 pm
Portfolio Pulse from Benzinga Newsdesk
October 25, 2024 | 11:16 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.